<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01424397</url>
  </required_header>
  <id_info>
    <org_study_id>111924</org_study_id>
    <nct_id>NCT01424397</nct_id>
  </id_info>
  <brief_title>Intranasal SB-705498 in Allergic Rhinitis (AR) Patients</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled, Incomplete Block, 3 Way Cross Over Study in Subjects With Allergic Rhinitis to Assess the Effect of Intranasal Repeat Doses of SB-705498 When Administered Alone or in Conjunction With Intranasal Fluticasone Propionate on the Symptoms of Rhinitis in the Vienna Allergen Challenge Chamber</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to look at the affect of SB-705498 on allergic rhinitis symptoms
      induced by an allergen chamber challenge.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TNSS scores D8 following allergen chamber challenge</measure>
    <time_frame>Day 8 of each treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Real life TNSS scores days 4-8</measure>
    <time_frame>Days 4-8 of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active Anterior Rhinomanometry (AAR) changes from baseline to D8</measure>
    <time_frame>Day 1 and Day 8 of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhinoconjunctivitis Quality of Life Questionnaire changes from baseline to D8</measure>
    <time_frame>Screening and Day 8 of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood levels of drug following 8 days of dosing</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Day 1 to Day 8 of each treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Rhinitis</condition>
  <arm_group>
    <arm_group_label>SB-705498</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flucticasone Propionate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SB-705498+FP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-705498</intervention_name>
    <description>12mg intranasal</description>
    <arm_group_label>SB-705498</arm_group_label>
    <arm_group_label>SB-705498+FP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FP</intervention_name>
    <description>200ug intranasal</description>
    <arm_group_label>Flucticasone Propionate</arm_group_label>
    <arm_group_label>SB-705498+FP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo intranasal</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of AR, as determined by the presence of rhinitis symptoms that last for
             several months per year, for more than 1 year and are not attributed to allergy,
             infections or nasal abnormalities.

          2. TNSS score of &gt;=4 following screening allergen challenge chamber.

          3. Positive skin prick test for seasonal pollen

          4. Positive RAST for seasonal pollen

          5. Healthy as determined by responsible physician with the exception of mild asthma and
             AR

          6. Male or female between 18 and 65 years of age inclusive.

          7. A female subject is eligible to participate if she is of:

               -  Non-childbearing potential defined as pre-menopausal females with a \documented
                  tubal ligation or hysterectomy; or postmenopausal defined as 12 months of
                  spontaneous amenorrhea [in questionable cases a blood sample with simultaneous
                  follicle stimulating hormone (FSH) &gt; 40 MlU/ml and estradiol &lt; 40 pg/ml (&lt;147
                  pmol/L) is confirmatory].

               -  Child-bearing potential and agrees to use one of the contraception methods listed
                  as instructed. Female subjects must agree to use contraception until 84 days
                  post-last treatment administration.

          8. Male subjects with female partners of child-bearing potential must agree to use one
             contraception as instructed. This must be followed from the time of the first dose of
             study medication until 84 days post-last treatment administration.

          9. Body weight ≥ 50 kg (males) and ≥45kg (females) and BMI within the range 19 - 29.9
             kg/m2 (inclusive).

         10. Screening pre-challenge FEV1 greater than or equal to 80% and baselines FEV1/FVC
             greater than or equal to 70% of predicted value.

         11. Capable of giving written informed consent.

         12. Average QTcB, &lt; 450 msec; or QTc &lt; 480 msec in subjects with Bundle Branch Block.

         13. AST and ALT &lt; 2xULN; alkaline phosphatase and bilirubin less than or equal to 1.5xULN

        Exclusion Criteria:

          1. Nasal abnormalities likely to affect the outcome of the study,

          2. History of frequent nosebleeds.

          3. Respiratory disease other than mild asthma

          4. A positive pre-study Hepatitis B or Hepatitis C result within 3 months of screening

          5. Current or chronic history of liver disease, or known hepatic or biliary abnormalities

          6. Positive pre-study drug/alcohol/smoking screen.

          7. A positive test for HIV antibody.

          8. History of regular alcohol consumption within 6 months of the study defined as:

             • An average weekly intake of &gt;14 drinks for males or &gt;7 drinks for females.

          9. The subject has participated in a clinical trial and has received an investigational
             product within 30 days, 5 half-lives or twice the duration of the biological effect of
             the investigational product prior to D1.

         10. Exposure to more than four new chemical entities within 12 months prior to D1.

         11. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
             supplements within 7 days prior to the first dose of study medication.

         12. History of sensitivity to any of the study medications, or components

         13. Where participation in the study would result in donation of blood or blood products
             in excess of 500 mL within a 56 day period.

         14. Pregnant females as determined by positive serum or urine hCG test at screening or
             prior to dosing.

         15. Lactating females.

         16. Subject is mentally or legally incapacitated.

         17. Urine cotinine levels indicative of smoking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vienna</city>
        <zip>A-1150</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Bareille P, Murdoch RD, Denyer J, Bentley J, Smart K, Yarnall K, Zieglmayer P, Zieglmayer R, Lemell P, Horak F. The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis. Int J Clin Pharmacol Ther. 2013 Jul;51(7):576-84. doi: 10.5414/CP201890.</citation>
    <PMID>23735181</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2011</study_first_posted>
  <last_update_submitted>November 18, 2016</last_update_submitted>
  <last_update_submitted_qc>November 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>111924</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111924</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111924</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111924</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111924</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111924</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111924</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <pending_results>
    <submitted>August 15, 2017</submitted>
    <returned>March 6, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

